Can Targeting the Incretin Pathway Dampen RAGE-Mediated Events in Diabetic Nephropathy?

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|17|11|1252-1264

ISSN： 1389-4501

Source： Current Drug Targets, Vol.17, Iss.11, 2016-07, pp. : 1252-1264

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting Adenosine Signaling to Treatment of Diabetic Nephropathy

By  

Current Drug Targets, Vol. 14, Iss. 4, 2013-04 ,pp. : 490-496

Bentham Science Publishers

Access to resources Recommend Favorite

Diabetic nephropathy

By Wylie Emma C   Satchell Simon C  

Clinical Medicine, Vol. 12, Iss. 5, 2012-10 ,pp. : 480-482

Royal College Of Physicians

Access to resources Recommend Favorite

IGF-1R Inhibitor Ameliorates Diabetic Nephropathy with Suppressed HMGN1/TLR4 Pathway

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 18, Iss. 3, 2018-04 ,pp. : 241-250

Bentham Science Publishers

Access to resources Recommend Favorite

Aliskiren a winner in diabetic nephropathy

By  

Inpharma, Vol. 1, Iss. 1642, 2008-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Losartan: In Diabetic Nephropathy

By Carswell C.I.   Goa K.L.  

Drugs, Vol. 63, Iss. 4, 2003-01 ,pp. : 407-414

Adis International

Access to resources Recommend Favorite